Simultaneous estimation of paclitaxel and erlotinib in plasma by liquid chromatography/(+) electrospray tandem mass spectrometry: application in formulation development and pharmacokinetics

References

• Gowda JI, Nandibewoor ST. Electrochemical behavior of paclitaxel and its determination at glassy carbon electrode. Asian J Pharm Sci. 2014;9:42–44 9.
   Google Scholar
• Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. 2013.
   Google Scholar
• Amalia M, Gugliemo N, Vincenzo I, et al. First line targeted therapies in breast cancer: focus on bevacizumab targets & therapy. Biologics. 2007;1(1):3–10.
   PubMedGoogle Scholar
• Khuroo T, Verma D, Khuroo A, et al. Simultaneous delivery of paclitaxel and erlotinib from dual drug loaded PLGA nanoparticles: formulation development, thorough optimization and in vitro release. J Mol Liquids. 2018;257:52–68.
   Web of Science ®Google Scholar
• Seshacharyulu P, Ponnusamy MP, Haridas D, et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):15–31.
   PubMed Web of Science ®Google Scholar
• Montagna E1, Cancello G, Bagnardi V, et al. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer. 2012;12(3):207–214.
   PubMed Web of Science ®Google Scholar
• Khuroo T, Atifa U, Iqbal Z. Oral formulation of paclitaxel and erlotinib polymeric nanoparticles: a potential combination to treat breast cancer. Biomed J Sci Techn Res. 2020;31(4):24338–24340.
   Google Scholar
• Fernández-Peralbo MA, Priego-Capote F, Luque de Castro MD, et al. LC-MS/MS quantitative analysis of paclitaxel and its major metabolites in serum, plasma and tissue from women with ovarian cancer after intra-peritoneal chemotherapy. J Pharm Biomed Anal. 2014;91:131–137.
   PubMed Web of Science ®Google Scholar
• Xia XJ, Peng J, Zhang PX, et al. Validated HPLC method for the determination of paclitaxel-related substances in an intravenous emulsion loaded with a paclitaxel–cholesterol complex. Indian J Pharm Sci. 2013;75(6):672–679.
   PubMed Web of Science ®Google Scholar
• Saadat E, Ravar F, Dehghankelishadi P, et al. Development and validation of a rapid RP-HPLC-DAD analysis method for the simultaneous quantitation of paclitaxel and lapatinib in a polymeric micelle formulation. ScientiaPharmaceutica. 2016;84(2):333–345.
   Google Scholar
• Partani P, Verma SM, Gurule S, et al. Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(–) electrospray tandem mass spectrometry. J Pharm Anal. 2014;4(1):26–36.
   PubMedGoogle Scholar
• Partani P, Verma SM, Monif T. Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: application to a bioequivalence study and metabolite identification. J Sep Sci. 2015;38(20):3533–3544. Oct
   PubMed Web of Science ®Google Scholar
• Bioanalytical Method Validation Guidance for Industry, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM), May 2018 Biopharmaceutics. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf.
   Google Scholar
• Keum CG, Noh YW, Baek JS, et al. Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid. Int J Nanomed. 2011;6:2225–2234.
   PubMed Web of Science ®Google Scholar
• Senthilkumar M, Mishra P, Jain NK. Long circulating PEGylatedpoly(D,L-lactide-co-glycolide) nanoparticulate delivery of docetaxel to solid tumors. J Drug Targeting. 2008;16:424–435.
   PubMed Web of Science ®Google Scholar
• Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-Loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Controlled Release. 2009;133:11–17.
   PubMed Web of Science ®Google Scholar
• Padhi S, Mirza MA, Verma D, et al. Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro behavior and tumor amelioration potential. Drug Delivery. 2016;23(8):2827–2837.
   PubMed Web of Science ®Google Scholar
• Hou W, Watters JW, McLeod HL. Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804:263–267.
   PubMed Web of Science ®Google Scholar
• Anzar N, Mirza MA, Anwer K, et al. Preparation, evaluation and pharmacokinetic studies of spray dried PLGA polymeric submicron particles of simvastatin for the effective treatment of breast cancer. J Mol Liq. 2018;249:609–616.
   Web of Science ®Google Scholar
• Costa P, Sousa Lobo JM. Evaluation of mathematical models describing drug release from estradiol transdermal systems. Drug Dev Ind Pharm. 2003;29(1):89–97.
   PubMed Web of Science ®Google Scholar
• Khuroo T, Verma D, Talegaonkar S, et al. Topotecan–tamoxifen duple PLGA polymeric nanoparticles: investigation of in vitro, in vivo and cellular uptake potential. Int J Pharm. 2014;473(1-2):384–394.
   PubMedGoogle Scholar
• López LZ, Pastor AA, Beitia A, et al. Determination of docetaxel and paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. Ther Drug Monit. 2006;28:199–205.
   PubMed Web of Science ®Google Scholar
• Wang LZ, Goh BC, Grigg ME, et al. A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. Rapid Communicationsin Mass Spectrometry. 2003;17:1548–1552.
   PubMed Web of Science ®Google Scholar
• Kuppens IE, Van Maanen MJ, Rosing H, et al. Quantitative analysis of docetaxelin human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr. 2005;19:355–361.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Zhao M, Brahmer JR, et al. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;773:183–181.
   PubMed Web of Science ®Google Scholar
• Calleja P, Espuelas S, Vauthier C, et al. Controlled release, intestinal transport, and oral bioavailablity of paclitaxel can be considerably increased using suitably tailored pegylated poly (anhydride) nanoparticles. J Pharm Sci. 2015;104(9):2877–2886.
   PubMed Web of Science ®Google Scholar
• Hurria A, Blanchard MS, Synold TW, et al. Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist. 2014;20:37–44.
   PubMed Web of Science ®Google Scholar
• Dora CP, Trotta F, Kushwah V, et al. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Carbohydr Polym. 2016;137:339–349.
   PubMed Web of Science ®Google Scholar
• Yang KM, Shin IC, Park JW, et al. Nanoparticulation improves bioavailability of erlotinib. Drug Dev Ind Pharm. 2017;43(9):1557–1565.
   PubMed Web of Science ®Google Scholar